{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:08:03Z","timestamp":1790356083469,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10147-026-03077-0","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:46:28Z","timestamp":1788367588000},"page":"2169-2178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-utility analysis of CAR-T therapy compared to standard of care in patients with relapsed\/refractory diffuse large B-cell lymphoma in Colombia, 2025"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0800-1388","authenticated-orcid":false,"given":"Alexandra","family":"Porras Ram\u00edrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4291-6135","authenticated-orcid":false,"given":"Alejandro","family":"Rico Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Encinales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Madiedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Fernanda","family":"Campos Maya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Fernando","family":"Ram\u00f3n Cuellar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5284-3022","authenticated-orcid":false,"given":"Jorge Andres","family":"Urquijo M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"3","key":"3077_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized Study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood 116(3):403\u2013410. https:\/\/doi.org\/10.1182\/blood-2010-03-276246","journal-title":"Blood"},{"issue":"26","key":"3077_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR-T cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"issue":"1","key":"3077_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"issue":"10254","key":"3077_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI et al (2020) Lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma (TRANSCEND NHL 001): a multicentre, seamless-design study. Lancet 396(10254):839\u2013852. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0","journal-title":"Lancet"},{"issue":"2","key":"3077_CR5","doi-asserted-by":"publisher","first-page":"e190242","DOI":"10.1001\/jamanetworkopen","volume":"2","author":"MD Whittington","year":"2019","unstructured":"Whittington MD, McQueen RB, Ollendorf DA et al (2019) Long-term survival and cost-utility analysis associated with axicabtagene ciloleucel versus chemotherapy for the treatment of relapsed\/refractory large B-cell lymphoma. JAMA Netw Open 2(2):e190242. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.0242","journal-title":"JAMA Netw Open"},{"issue":"27","key":"3077_CR6","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/JCO.19.03090","volume":"38","author":"JK Lin","year":"2020","unstructured":"Lin JK, Muffly LS, Spinner MA et al (2020) Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. J Clin Oncol 38(27):3217\u20133228. https:\/\/doi.org\/10.1200\/JCO.19.03090","journal-title":"J Clin Oncol"},{"key":"3077_CR7","unstructured":"NICE (2021) Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after two or more systemic therapies. Technol Appraisal TA872"},{"issue":"2","key":"3077_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s41669-021-00312-4","volume":"6","author":"A Olry de Labry Lima","year":"2022","unstructured":"Olry de Labry Lima A, Berm\u00fadez-Tamayo C, Prada-Ramallal G et al (2022) Cost-utility analysis of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in Spain. Pharmacoecon Open 6(2):237\u2013247. https:\/\/doi.org\/10.1007\/s41669-021-00312-4","journal-title":"Pharmacoecon Open"},{"key":"3077_CR9","unstructured":"Canadian Agency for Drugs and (2021) Technologies in Health (CADTH). Axicabtagene ciloleucel: Economic Review Report. CADTH"},{"key":"3077_CR10","volume-title":"Gu\u00eda Metodol\u00f3gica para la Elaboraci\u00f3n de Evaluaciones Econ\u00f3micas en Salud","author":"IETS Colombia","year":"2014","unstructured":"IETS Colombia (2014) Gu\u00eda Metodol\u00f3gica para la Elaboraci\u00f3n de Evaluaciones Econ\u00f3micas en Salud. Instituto de Evaluaci\u00f3n Tecnol\u00f3gica en Salud, Bogot\u00e1"},{"issue":"1","key":"3077_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20(1):31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"issue":"10254","key":"3077_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"LI","year":"2020","unstructured":"Li et al (2020) Lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma (TRANSCEND NHL 001): a multicentre, seamless-design study. Lancet 396(10254):839\u2013852. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0","journal-title":"Lancet"},{"key":"3077_CR13","doi-asserted-by":"publisher","unstructured":"G\u00f3mez LF (2022) Estimating the health opportunity cost of health spending in Colombia: a cross-sectoral marginal productivity analysis. Value Health Reg Issues. 29:10\u201318. https:\/\/doi.org\/10.1016\/j.vhri.2022.05.003","DOI":"10.1016\/j.vhri.2022.05.003"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03077-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03077-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03077-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:50:35Z","timestamp":1790355035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03077-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3077"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03077-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This Study is a cost-utility analysis based exclusively on secondary data obtained from published clinical trials, aggregated outcomes, and publicly available cost sources. No individual patient-level data were collected, accessed, or analyzed, and no human participants were directly involved in the conduct of this research. Therefore, approval by an institutional review board or ethics committee and informed consent were not required. In accordance with Colombian regulations, this Study qualifies as research without risk under Resolution 8430 of 1993 of the Colombian Ministry of Health, which governs health research ethics. The Study was conducted in compliance with internationally accepted ethical principles for research integrity and health economic evaluations.","order":2,"name":"Ethics","label":"Ethical Considerations","group":{"name":"EthicsHeading","label":"Declarations"}}]}}